[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-detail-335778-en":59,"doc-seo-335778-105":82},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":5,"data":60},{"doc_id":61,"user_id":62,"nickname":63,"user_avatar":64,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":66,"doc_content":67,"file_id":68,"file_url":69,"file_type":70,"file_size":71,"view_count":72,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":73,"language":74,"language_code":75,"site_id":76,"html_lang":75,"table_of_contents":77,"faqs":78,"seo_title":79,"seo_description":66,"update_tm":80,"read_time":81,"preview_page_count":4},335778,13056703020460,"Valentina","https://ap-avatar.wpscdn.com/avatar/be000253dac470eee5d?_k=1778207105932848923","Targeting KRAS-mutant pancreatic cancer through simultaneous inhibition of KRAS - MEK, and JAK2","KRAS is a major driver in pancreatic cancer, yet single-agent KRAS inhibitors can trigger feedback that reactivates ERK and increases STAT3 phosphorylation, limiting therapeutic impact. This study tests whether combining KRAS blockade with MAPK and JAK2 pathway suppression can overcome adaptive signaling. Sotorasib or MRTX1133 increased STAT3 phosphorylation and reactivated ERK; adding trametinib (MEK inhibitor) and fedratinib (JAK2 inhibitor) reversed these effects and produced significant growth inhibition in vitro and in vivo. In addition, combined trametinib plus fedratinib restored sensitivity in sotorasib- and MRTX1133-resistant cells, supporting KRAS - MEK - JAK2 co-inhibition as a novel strategy.","Targeting KRAS-mutant pancreatic cancer through simultaneous inhibition of KRAS, MEK, and JAK2  \nSatoru Miyazaki 1, Masato Kitazawa 1 , Satoshi Nakamura 1, Makoto Koyama 1, Yuta Yamamoto 1, Nao Hondo 1, Masahiro Kataoka 1, Hirokazu Tanaka 1, Michiko Takeoka 1, Daisuke Komatsu2 and Yuji Soejima 1  \n1 Division of Gastroenterological, Hepato-Biliary-Pancreatic, Transplantation and Pediatric Surgery, Department of Surgery, Shinshu University School of Medicine, Matsumoto, Japan  \n2 Department of Surgery, Jinai Hospital, Ina, Japan  \nKeywords  \nfedratinib; KRAS; MRTX1133; pancreatic cancer; sotorasib; trametinib  \nCorrespondence  \nM. Kitazawa, Division of Gastroenterological, Hepato-Biliary-Pancreatic, Transplantation and Pediatric Surgery, Department of Surgery, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan  \nFax +81 263 35 1282 Tel: +81 263 37 2654  \nE-mail: [kita118@shinshu-u.ac.jp](kita118@shinshu-u.ac.jp)  \n(Received 2 March 2024, revised 2 August 2024, accepted 3 October 2024, available online 14 October 2024)  \ndoi:10 . 1002/1878-0261 .13751  \nThe Kirsten rat sarcoma (KRAS) oncogene was considered “undruggable”until the development of sotorasib, a KRASG12C selective inhibitor that shows favorable effects against lung cancers. MRTX1133, a novel KRASG12D inhibitor, has shown promising results in basic research, although its effects against pancreatic cancer are limited when used alone. Therefore, there is an urgent need to identify effective drugs that can be used in combination with KRAS inhibitors. In this study, we found that administration of the KRAS inhibitors sotorasib or MRTX1133 upregulated STAT3 phosphorylation and reactivated ERK through a feedback reaction. The addition of the MEK inhibitor trametinib and the JAK2 inhibitor fedratinib successfully reversed this effect and resulted in signiﬁcant growth inhibition in vitro and in vivo. Analyses of sotorasib- and MRTX1133-resistant cells showed that trametinib plus fedratinib reversed the resistance to sotorasib or MRTX1133 . These ﬁndings suggest that the JAK2-mediated pathway and reactivation of the MAPK pathway may play key roles in resistance to KRAS inhibitors in pancreatic cancers. Accordingly, simultaneous inhibition of KRAS, MEK, and JAK2 could be an innovative therapeutic strategy against KRAS-mutant pancreatic cancer.  \n1. Introduction  \nPancreatic cancer is the third leading cause of cancer-related deaths in the United States and fourth in Japan [1,2] . According to the latest Japanese statistics, the 5-year survival rate for pancreatic cancer is only 12.1%, which is signiﬁcantly lower than that for other cancers such as bile duct cancer (28 .7%), esophageal cancer (50.1%), and colorectal cancer (76.8%)  \n[2] . While only 20% of patients with pancreatic cancer undergo curative resection [3], effective molecule-based therapies against pancreatic cancer are lacking. Treatment with FOLFIRINOX, a combination of ﬂuorouracil, leucovorin, irinotecan, oxaliplatin, and gemcitabine with nab-paclitaxel (GEM-NABP), has shown superior effects in patients with pancreatic  \nAbbreviations  \nAKT, protein kinase B; ANOVA, analysis of variance; CCK-8, cell counting kit-8; EGFR, epidermal growth factor receptor; ERK, extracellular signal-regulated kinase; GEM-NABP, gemcitabine with nab-paclitaxel; IHC, immunohistochemical; JAK2, Janus kinase 2; KRAS, Kristen rat sarcoma; MEK, mitogen-activated protein kinase; NRTK, neurotrophic tropomyosin-receptor kinase; PDAC, pancreatic ductaladenocarcinoma; PI3K, phosphatidylinositol-3 kinase; RTK, receptor tyrosine kinase; STAT3, signal transducer and activator of transcription 3; TRK, tropomyosin-related kinase.  \nMolecular Oncology 19 (2025) 377–390 ª 2024 The Author(s) . Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, dis","cbCaif8Koz91LUsE","https://ap.wps.com/l/cbCaif8Koz91LUsE","pdf",8129181,12,14,"English","en",105,"# Introduction\n## Background on pancreatic cancer and KRAS-driven signaling\n## Rationale for combined KRAS, MEK, and JAK2 inhibition\n## Overview of existing therapies and unmet needs","[{\"question\":\"Why are KRAS inhibitors insufficient as single-agent therapy in KRAS-mutant pancreatic cancer?\",\"answer\":\"KRAS inhibitors such as sotorasib or MRTX1133 upregulate STAT3 phosphorylation and reactivate ERK via a feedback reaction, weakening their anti-tumor effect when used alone.\"},{\"question\":\"What was the effect of adding trametinib and fedratinib to KRAS inhibitors?\",\"answer\":\"The combination reversed KRAS inhibitor–induced STAT3/ERK reactivation and resulted in significant growth inhibition in both in vitro and in vivo settings.\"},{\"question\":\"How did the combined treatment perform against KRAS inhibitor-resistant cells?\",\"answer\":\"Analyses of sotorasib- and MRTX1133-resistant cells showed that trametinib plus fedratinib reversed resistance to either KRAS inhibitor.\"}]","Targeting KRAS-mutant pancreatic cancer through simultaneous inhibition of KRAS - MEK, and JAK2 | PDF",1790012301,35,{"code":4,"msg":83,"data":84},"ok",{"site_id":76,"language":75,"slug":85,"title":65,"keywords":86,"description":66,"schema_data":87,"social_meta":141,"head_meta":143,"extra_data":145,"updated_unix":146},"targeting-kras-mutant-pancreatic-cancer-through-simultaneous-inhibition-of-kras-mek-and-jak2","",{"@graph":88,"@context":140},[89,103,123],{"@type":90,"itemListElement":91},"BreadcrumbList",[92,96,98,101],{"item":93,"name":94,"@type":95,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":97,"name":9,"@type":95,"position":14},"https://docshare.wps.com/document/",{"item":99,"name":40,"@type":95,"position":100},"https://docshare.wps.com/document/research-report/",3,{"item":102,"name":65,"@type":95,"position":19},"https://docshare.wps.com/document/targeting-kras-mutant-pancreatic-cancer-through-simultaneous-inhibition-of-kras-mek-and-jak2/335778/",{"url":102,"name":65,"@type":104,"image":105,"author":110,"headline":65,"publisher":112,"fileFormat":115,"inLanguage":75,"description":66,"dateModified":116,"datePublished":117,"encodingFormat":115,"isAccessibleForFree":118,"interactionStatistic":119},"DigitalDocument",{"url":106,"@type":107,"width":108,"height":109},"https://docshare.wps.com/thumbnails/targeting-kras-mutant-pancreatic-cancer-through-simultaneous-inhibition-of-kras-mek-and-jak2/335778.png","ImageObject",300,407,{"name":63,"@type":111},"Person",{"url":93,"name":113,"@type":114},"DocShare","Organization","application/pdf","2026-11-01","2026-09-21",true,{"@type":120,"interactionType":121,"userInteractionCount":72},"InteractionCounter",{"@type":122},"ViewAction",{"@type":124,"mainEntity":125},"FAQPage",[126,132,136],{"name":127,"@type":128,"acceptedAnswer":129},"Why are KRAS inhibitors insufficient as single-agent therapy in KRAS-mutant pancreatic cancer?","Question",{"text":130,"@type":131},"KRAS inhibitors such as sotorasib or MRTX1133 upregulate STAT3 phosphorylation and reactivate ERK via a feedback reaction, weakening their anti-tumor effect when used alone.","Answer",{"name":133,"@type":128,"acceptedAnswer":134},"What was the effect of adding trametinib and fedratinib to KRAS inhibitors?",{"text":135,"@type":131},"The combination reversed KRAS inhibitor–induced STAT3/ERK reactivation and resulted in significant growth inhibition in both in vitro and in vivo settings.",{"name":137,"@type":128,"acceptedAnswer":138},"How did the combined treatment perform against KRAS inhibitor-resistant cells?",{"text":139,"@type":131},"Analyses of sotorasib- and MRTX1133-resistant cells showed that trametinib plus fedratinib reversed resistance to either KRAS inhibitor.","https://schema.org",{"og:url":102,"og:type":142,"og:title":65,"og:site_name":113,"og:description":66},"article",{"robots":144,"canonical":102},"index,follow",{"doc_id":61,"site_id":76},1790032662]